Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-1801 for Cystic Fibrosis Pulmonary Exacerbations
NCT05641298Phase 2Withdrawn
- Sponsor
- Aceragen, Inc.
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ACG-701 in cystic fibrosis (CF), sponsored by Aceragen, Inc.. Planned start Feb 2023; status: withdrawn.
02
Drugs
ACG-701
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05641298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641298.